Literature DB >> 26548897

Novel systemic therapies for the treatment of psoriasis.

Ki-Wei Tan1,2, Christopher E M Griffiths1.   

Abstract

INTRODUCTION: The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently. AREAS COVERED: Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments. EXPERT OPINION: The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.

Entities:  

Keywords:  IL-17; IL-23; JAK inhibitor; biologic; novel; phosphodiesterase-4 inhibitor; psoriasis; small molecules; systemic

Mesh:

Substances:

Year:  2015        PMID: 26548897     DOI: 10.1517/14656566.2016.1109636

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.

Authors:  Alexandra Zanin-Zhorov; Jonathan M Weiss; Alissa Trzeciak; Wei Chen; Jingya Zhang; Melanie S Nyuydzefe; Carmen Arencibia; Seetharam Polimera; Olivier Schueller; Judilyn Fuentes-Duculan; Kathleen M Bonifacio; Norma Kunjravia; Inna Cueto; Jennifer Soung; Roy M Fleischmann; Alan Kivitz; Mark Lebwohl; Margarita Nunez; Johnnie Woodson; Shondra L Smith; Robert F West; Mark Berger; James G Krueger; John L Ryan; Samuel D Waksal
Journal:  J Immunol       Date:  2017-04-07       Impact factor: 5.422

Review 2.  Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?

Authors:  Alessandro Mantovani; Paolo Gisondi; Amedeo Lonardo; Giovanni Targher
Journal:  Int J Mol Sci       Date:  2016-02-05       Impact factor: 5.923

3.  Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study.

Authors:  Giovanni Pellacani; Laura Bigi; Aurora Parodi; Martina Burlando; Caterina Lanna; Elena Campione; Franco Rongioletti; Cristina Mugheddu; Giovanna Malara; Giovanna Moretti; Luca Stingeni; Katharina Hansel; Giuseppe Micali; Luigi Naldi; Federico Pirro; Ketty Peris
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

Review 4.  Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions.

Authors:  Adriana Borriello; Ilaria Caldarelli; Debora Bencivenga; Emanuela Stampone; Silverio Perrotta; Adriana Oliva; Fulvio Della Ragione
Journal:  Oncotarget       Date:  2017-01-17

5.  Chinese Medicine for Psoriasis Vulgaris Based on Syndrome Pattern: A Network Pharmacological Study.

Authors:  Dongmei Wang; Chuanjian Lu; Jingjie Yu; Miaomiao Zhang; Wei Zhu; Jiangyong Gu
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-28       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.